We are live on ! Find out more

171 hedge funds and large institutions have $3.24B invested in Insmed in 2019 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 83 increasing their positions, 34 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 34

75% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 20

38.78% more ownership

Funds ownership: 106.05%144.83% (+39%)

35% more capital invested

Capital invested by funds: $2.39B → $3.24B (+$846M)

8% more funds holding

Funds holding: 158171 (+13)

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

36% less call options, than puts

Call options by funds: $9.82M | Put options by funds: $15.3M

Holders
171
Holders Change
+13
Holders Change %
+8.23%
% of All Funds
3.71%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.15%
New
35
Increased
83
Reduced
34
Closed
20
Calls
$9.82M
Puts
$15.3M
Net Calls
-$5.5M
Net Calls Change
-$9.75M
Name Holding Trade Value Shares
Change
Change in
Stake
AAMU
1
Amundi Asset Management US
Massachusetts
$794M +$864M +31,022,000 +402,883%
Janus Henderson Group
2
Janus Henderson Group
United Kingdom
$299M +$10.1M +361,756 +3%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$271M -$29M -1,042,068 -9%
Vanguard Group
4
Vanguard Group
Pennsylvania
$204M +$25M +896,047 +13%
PAI
5
Palo Alto Investors
California
$202M +$6.61M +237,300 +3%
BlackRock
6
BlackRock
New York
$185M -$62.4K -2,240 -0%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$181M -$23.1M -827,528 -10%
State Street
8
State Street
Massachusetts
$81.4M +$9.45M +339,110 +12%
BBA
9
Baker Bros. Advisors
New York
$63M +$10.7M +384,615 +19%
Citadel Advisors
10
Citadel Advisors
Florida
$59.4M +$32.8M +1,176,356 +103%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$56.8M +$45.3M +1,625,381 +274%
VC
12
Vivo Capital
California
$44.8M +$16.1M +577,884 +49%
CCM
13
Consonance Capital Management
New York
$43.8M +$47.7M +1,711,150 New
FCMI
14
Foresite Capital Management IV
California
$40M +$761K +27,302 +2%
EAM
15
Eagle Asset Management
Florida
$38.4M +$41.8M +1,501,558 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$28.2M +$4.01M +144,017 +15%
CTA
17
Carillon Tower Advisers
Florida
$26.8M +$29.1M +1,046,301 New
Northern Trust
18
Northern Trust
Illinois
$25M +$830K +29,797 +3%
FCMI
19
Foresite Capital Management II
California
$24.5M +$1M +36,026 +4%
Norges Bank
20
Norges Bank
Norway
$23.5M +$4.46M +160,207 +21%
EA
21
Emerald Advisers
Pennsylvania
$23.4M -$167K -6,008 -0.7%
RSCM
22
Rock Springs Capital Management
Maryland
$22.8M +$1.11M +40,000 +5%
EMFAT
23
Emerald Mutual Fund Advisers Trust
Pennsylvania
$21.6M +$31.4K +1,127 +0.1%
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$19.1M +$18.8M +675,166 +936%
ACM
25
Asymmetry Capital Management
California
$18.7M +$16M +575,553 +372%

INSM Hedge Fund Activity: Q2 2019 in Review

171 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q2 2019, worth a combined $3.24B — up 35% from $2.39B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new INSM positions and 20 closed out — a net gain of 15 holders — while 83 added to existing stakes and 34 trimmed.

The largest buyer was Amundi Asset Management US, adding an estimated $864M. The largest seller was Fidelity Investments, cutting an estimated $29M.

  • 171 institutional investors held Insmed (INSM) as of Q2 2019, up from 158 in Q1 2019.
  • Funds reported $3.24B of Insmed stock for Q2 2019, up 35% quarter-over-quarter.
  • 35 funds opened new Insmed positions in Q2 2019 and 20 closed out, a net change of +15 holders.
  • The largest Insmed buyer in Q2 2019 was Amundi Asset Management US, an estimated $864M added.
  • The largest Insmed seller in Q2 2019 was Fidelity Investments, an estimated $29M sold.

Based on aggregated 13F filings for Q2 2019.